The current state of serum biomarkers of hepatotoxicity.

Authors:
Dr. Marcia Ratner, PhD, DABT
Dr. Marcia Ratner, PhD, DABT
Department of Pharmacology and Experimental Therapeutics,Boston University School of Medicine
Project Manager
Toxicology, Neurology, Pharmacology
Boston, Massachusetts | United States

Toxicology 2008 Mar 5;245(3):194-205. Epub 2007 Dec 5.

Safety Assessment, Merck Research Laboratories, West Point, PA, USA.

The level of serum alanine aminotransferase (ALT) activity reflects damage to hepatocytes and is considered to be a highly sensitive and fairly specific preclinical and clinical biomarker of hepatotoxicity. However, an increase in serum ALT activity level has also been associated with other organ toxicities, thus, indicating that the enzyme has specificity beyond liver in the absence of correlative histomorphologic alteration in liver. Thus, unidentified non-hepatic sources of serum ALT activity may inadvertently influence the decision of whether to continue development of a novel pharmaceutical compound. To assess the risk of false positives due to extraneous sources of serum ALT activity, additional biomarkers are sought with improved specificity for liver function compared to serum ALT activity alone. Current published biomarker candidates are reviewed herein and compared with ALT performance in preclinical and on occasion, clinical studies. An examination of the current state of hepatotoxic biomarkers indicates that serum F protein, arginase I, and glutathione-S-transferase alpha (GSTalpha) levels, all measured by ELISA, may show utility, however, antibody availability and high cost per run may present limitations to widespread applicability in preclinical safety studies. In contrast, the enzymatic markers sorbitol dehydrogenase, glutamate dehydrogenase, paraxonase, malate dehydrogenase, and purine nucleoside phosphorylase are all readily measured by photometric methods and use reagents that work across preclinical species and humans and are commercially available. The published literature suggests that these markers, once examined collectively in a large qualification study, could provide additional information relative to serum ALT and aspartate aminotransferase (AST) values. Since these biomarkers are found in the serum/plasma of treated humans and rats, they have potential to be utilized as bridging markers to monitor acute drug-induced liver injury in early clinical trials.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.tox.2007.11.021DOI Listing

Still can't find the full text of the article?

We can help you send a request to the authors directly.
March 2008
50 Reads
155 Citations
3.621 Impact Factor

Publication Analysis

Top Keywords

alt activity
20
serum alt
20
specificity liver
8
sources serum
8
serum
8
current state
8
alt
7
activity
5
preclinical occasion
4
occasion clinical
4
clinical studies
4
studies examination
4
study provide
4
performance preclinical
4
compared alt
4
provide additional
4
alt performance
4
examination current
4
serum protein
4
biomarkers indicates
4

Altmetric Statistics

Similar Publications